about
Erythropoiesis-stimulating agents for myelodysplastic syndromesGrowth factors for treating diabetic foot ulcersProlonged storage of packed red blood cells for blood transfusionJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisHomocysteine-lowering interventions for preventing cardiovascular eventsImatinib for treating newly diagnosed chronic myeloid leukemia patientsTreatment for disseminated intravascular coagulation in patients with acute and chronic leukemiaVitamin K for upper gastrointestinal bleeding in people with acute or chronic liver diseasesAntifibrinolytic amino acids for upper gastrointestinal bleeding in people with acute or chronic liver diseaseInterventions for treating intrahepatic cholestasis in people with sickle cell diseaseAcetyl-L-carnitine for patients with hepatic encephalopathyProphylactic lidocaine for myocardial infarctionAntibiotic therapy for adults with neurosyphilisEculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaAntibiotics for gonorrhoea in pregnancyTreatment for avascular necrosis of bone in people with sickle cell diseaseTreatment for avascular necrosis of bone in people with sickle cell diseaseAntibiotics for treating community acquired pneumonia in people with sickle cell diseaseAutologous platelet-rich plasma for treating chronic woundsAntibiotic therapy for treatment of infective endocarditisAutologous platelet-rich plasma for treating surgical woundsVitamin K for upper gastrointestinal bleeding in patients with acute or chronic liver diseasesAntifibrinolytic amino acids for upper gastrointestinal bleeding in patients with acute or chronic liver diseaseInterventions for preventing high altitude illnessErythropoiesis-stimulating agents for anemia in rheumatoid arthritisInterventions for treating intrahepatic cholestasis in people with sickle cell diseaseHuman recombinant activated protein C for severe sepsisEculizumab for treating patients with paroxysmal nocturnal hemoglobinuriaHuman recombinant activated factor VII for upper gastrointestinal bleeding in patients with liver diseasesLeukoreduction for the prevention of adverse reactions from allogeneic blood transfusionAntibiotics for treating acute chest syndrome in people with sickle cell diseaseHomocysteine-lowering interventions for preventing cardiovascular eventsJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisAntibiotics for treating osteomyelitis in people with sickle cell diseaseErythropoiesis-stimulating agents for myelodysplastic syndromesPharmacological interventions for treating heart failure in patients with Chagas cardiomyopathyInterventions for treating leg ulcers in people with sickle cell diseaseInterventions for treating high altitude illnessErythropoiesis-stimulating agents for anemia in rheumatoid arthritisHaematological interventions for treating disseminated intravascular coagulation during pregnancy and postpartum
P50
Q24186244-25A9E418-F52F-44DF-AD1C-945E09407C5BQ24186333-092E9ED0-87B9-4B88-B773-A6D61315F751Q24186513-D832F6DD-6D0E-49DE-B0C2-FD61F50BE090Q24186554-768261A3-48C7-4395-8141-E649DDE163C5Q24186605-CA848E72-7B69-43AF-803A-528CC88E46A2Q24186877-613CC7EE-DE9D-4EF7-AD50-40AE5053C01DQ24187024-3E8399FE-0E08-448B-A58E-521EA632AFF4Q24187239-7345EA8C-FB2A-4EB4-9701-2101F202453FQ24187246-283704AF-6CE6-43AA-A1F8-D16A33AFB207Q24187279-DB9ADE80-3F7B-45D0-89B6-22F9C5DD584DQ24187553-18CBA84F-C200-444B-B89F-0A194DAA9E2FQ24187816-897B9BF4-5814-4DFE-9D11-37CC7DDC0ABCQ24188209-1923CCE0-D0F7-4A3F-880C-B49A76C4CEF4Q24193045-3E8678CD-7F9A-46FD-A91D-7FF4E359BE29Q24194307-1A1BBE4F-675D-478E-9C2F-8BE32976CB4AQ24194880-B5D4BFF2-82CF-4C22-ACD6-CCD4CD191F88Q24197657-CD290596-0506-4309-AFD9-6D57C9F6621DQ24197977-94E9AF82-9244-4948-B957-1308DD410D23Q24198209-D2B75B86-F47D-46EF-91DE-519D5D041957Q24198788-743EE3A1-3E4A-4EC2-95D6-08A89597E71AQ24198933-0B91AC7E-E32D-4692-97BD-C0FB2843E2E7Q24200416-E86A267A-83B0-4F8C-AC04-B592BCEE5CE1Q24200420-CD72E8F7-CBB1-4DF6-91BA-1F97FABC3F2FQ24200658-31ACE67E-AC60-488E-9C13-FF1BC31A2D96Q24200775-A3108C60-64CC-43BB-A48D-36F59758E945Q24200803-378FFC34-A8FF-4BFB-8BEB-C4F13780AB5CQ24201123-F3A6006A-8362-421B-A0A1-77444F49F7BBQ24201126-208682D5-8206-43A8-BC05-0CC356D545ABQ24201303-445E9B7F-36EC-4F93-A19E-AE6DC0DEDBA6Q24201602-61BFE34A-BB9C-430C-8529-7E9BE180935FQ24201706-D8C047B5-0225-4BDF-BFE2-CCC15A981BE4Q24201783-D26BB35F-BCE4-454E-90D1-521DC5817B3CQ24201893-FE4EDD0A-F558-419B-A365-BC8153098909Q24202271-DF1A9A7E-9BC5-4C6C-8DB0-6C84C517AA6AQ24202526-3000AEFD-03DE-4345-83B5-74508991F3AEQ24202908-578AAFFD-0E3C-4D00-9A7F-B1BE26B8D842Q24202954-E01217CE-E15C-4E75-9B74-C9A4D521C091Q24203956-2109DCF2-11FB-409A-8810-83A7AA2159FBQ24234260-F4E4CFCD-6769-4A3E-8A17-F04A8EE09B8BQ24234663-9C7BE0B6-749B-45C6-8722-CD3E35626154
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Arturo J Martí-Carvajal
@ast
Arturo J Martí-Carvajal
@en
Arturo J Martí-Carvajal
@es
type
label
Arturo J Martí-Carvajal
@ast
Arturo J Martí-Carvajal
@en
Arturo J Martí-Carvajal
@es
prefLabel
Arturo J Martí-Carvajal
@ast
Arturo J Martí-Carvajal
@en
Arturo J Martí-Carvajal
@es